Amgen's HZN-1116 Phase 2 Study Shows Promise for Sjögren's Syndrome Treatment

Amgen announced an update on their ongoing Phase 2 study of HZN-1116 for Sjögren's Syndrome. The study aims to assess the drug's efficacy and safety in treating the chronic autoimmune condition. HZN-1116 is administered subcutaneously and designed to alleviate symptoms of Sjögren's Syndrome. The study started in May 2024 and is expected to complete in mid-2025. Successful results could positively impact Amgen's stock and lead to a new treatment option for patients.